Intravenous IgM-enriched immunoglobulins in critical COVID-19: a multicentre propensity-weighted cohort study

Intravenous IgM-enriched immunoglobulins in critical COVID-19: a multicentre propensity-weighted cohort study

Background: A profound inflammation-mediated lung injury with long-term acute respiratory distress and high mortality is one of the major complications of critical COVID-19. Immunoglobulin M (IgM)-enriched immunoglobulins seem especially capable of mitigating the inflicted inflammatory harm. However...

Full description

Bibliographic Details
Main Authors: Achtzehn, U. (Author), Adamzik, M. (Author), Basten, J. (Author), Brandenburger, T. (Author), Dietrich, M. (Author), Haberl, H. (Author), Jarczak, D. (Author), Kindgen-Milles, D. (Author), Koch, T. (Author), Kraft, F. (Author), Landgraf, C. (Author), Magunia, H. (Author), Meybohm, P. (Author), Neb, H. (Author), Nierhaus, A. (Author), Rahmel, T. (Author), Rosenberger, P. (Author), Timmesfeld, N. (Author), Ullrich, R. (Author), Weigand, M.A (Author), Zacharowski, K. (Author), Zimmer, F. (Author)
Format: Article
Language:English
Published: BioMed Central Ltd 2022
Subjects:
Coronavirus disease
COVID-19
Immunoglobulin M
Immunoglobulins
SARS-CoV-2
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items